UNDERSTANDING HEART FAILURE BURDEN IN MIDDLE EAST COUNTRIES- ECONOMIC IMPACT IN EGYPT, SAUDI ARABIA AND UNITED ARAB EMIRATES

Author(s)

AlHabeeb W¹, Akhras K², AlGhalayini K³, Al-Mudaiheem H⁴, Ibrahim B⁵, Lawand S⁶, Al-Ayoubi F⁷, ElSalah R⁸, Shaikh A⁹, Bader F¹⁰
¹Kind Saud University, Riyadh, Saudi Arabia, ²Novartis AG, Dubai, United Arab Emirates, ³King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia, ⁴Ministry of Health, Riyadh, Saudi Arabia, ⁵North Cumbria Universty Hospitals, Carlisle, UK, ⁶Dallah Hospital, Riyadh, Saudi Arabia, ⁷King Saud University, Riyadh, Saudi Arabia, ⁸Novartis Pharma Services, Dubai, United Arab Emirates, ⁹Ernst & Young (Dubai Branch), Dubai, United Arab Emirates, ¹⁰Cleveland Clinic Abu Dhabi., Abu Dhabi, United Arab Emirates

OBJECTIVES: The economic burden of chronic heart failure (HF) is well characterized in Developed markets but is not well understood in the Middle East (ME) despite high prevalence of heart diseases. The objective of this study is to estimate the healthcare resources (HCR) and direct costs of HF care in three Middle Eastern countries: Egypt (EG), Saudi Arabia (SA) and the United Arab Emirates (UAE).

METHODS: Survey questionnaire was developed and used in interview with leading heart failure specialists, cardiologists and/or clinical pharmacists in each country to collect HCR and costs from their respective institutions in both private and public sectors. HCR (diagnostics, physician visits, medications, inpatient admission, ER, invasive procedures) used in routine management of their HF patients were included. National cost of HF was estimated by summing the total cost of HF in each sector, and was used to calculate the average annual cost per patient. Given the lack of epidemiology data on HF in the region, we used the US prevalence rate of 2.4% in >20 years population adjusted for age distribution in the three ME countries. Costs were in local currency and converted to Unites States Dollars (USD) using current exchange rates for respective currencies.

RESULTS: An estimated 1.35 million patients are being treated for HF (EG=931,135; SA=320,933; UAE=93,865). The total estimated costs is US $ 1.92 Billion (EG=$0.356B; SA=$1.045B; UAE=$0.519B). Annual per-patient costs was highest in UAE followed by SA and EG (US $13,836; $8,137; $850, respectively). Inpatient admission cost was the major cost driver ranging from 25% to 56%.

CONCLUSIONS: In absence of health insurance claims databases that can be used to quantify the national cost of HF in ME countries, the interview method used indicates that HF is a costly disease with inpatient admission costs being the key cost driver.

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PHS23

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation